Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| TTP488-201 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Trans Tech Pharmaceuticals | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A 10-week safety and tolerability study of a potential treatment for mild to moderate Alzheimer's disease.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Low Dose Arm | Experimental |
| |
| High Dose Arm | Experimental |
| |
| Placebo Control | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PF-04494700 - Low Dose Arm | Drug | 30 mg loading dose for 6 days, followed by 10 mg daily |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Safety Measures include Adverse Events | Every Visit | |
| Laboratory Tests | Every Office Visit | |
| 12-Lead Electrocardiogram | Every Office Visit | |
| 24-Hour 12-Lead Serial ECGs | Baseline, Study End |
| Measure | Description | Time Frame |
|---|---|---|
| Surrogate Efficacy Markers in Plasma: A-Beta, C-Reactive Protein, IL-1, IL-6, Isoprostanes, TNF-alpha, TNF-beta | Baseline, Visit 5, Study End | |
| Cognitive Function Tests: ADAS-Cog, CDR-Sum of Boxes, MMSE, ADCS-ADL | Screening Visit, Baseline, Study End |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Sun City | Arizona | 85351 | United States | ||
| Pfizer Investigational Site |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| PF-04494700 - High Dose Arm |
| Drug |
60 mg loading dose for 6 days, followed by 20 mg daily |
|
| Placebo Comparator | Drug | Matching placebo. |
|
| Pharmacokinetic Profile | Baseline and Every Office Visit |
| Fresno |
| California |
| 93720 |
| United States |
| Pfizer Investigational Site | San Diego | California | 92103 | United States |
| Pfizer Investigational Site | San Francisco | California | 94118 | United States |
| Pfizer Investigational Site | Fort Lauderdale | Florida | 33321 | United States |
| Pfizer Investigational Site | Fort Myers | Florida | 33912 | United States |
| Pfizer Investigational Site | Hallandale | Florida | 33009 | United States |
| Pfizer Investigational Site | Jacksonville | Florida | 32216 | United States |
| Pfizer Investigational Site | Largo | Florida | 33773 | United States |
| Pfizer Investigational Site | Orlando | Florida | 32806 | United States |
| Pfizer Investigational Site | West Palm Beach | Florida | 33407 | United States |
| Pfizer Investigational Site | Memphis | Tennessee | 38119 | United States |
| ID | Term |
|---|---|
| D000544 | Alzheimer Disease |
| ID | Term |
|---|---|
| D003704 | Dementia |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D024801 | Tauopathies |
| D019636 | Neurodegenerative Diseases |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided